GlassScriptPhysician profile
Sunita Ravikumar
NPI 1376602797
$1,923.87
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $334 · 2020: $389 · 2021: $545 · 2022: $501 · 2023: $126 · 2024: $28.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $154.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,143.10 | 2019-2023 | Farxiga |
| Medtronic, INC. | $294.31 | 2021-2024 | Inpen Smart Insulin Delivery System, Minimed 780g |
| Boehringer Ingelheim Pharmaceuticals, INC. | $133.53 | 2019 | |
| Lilly USA, LLC | $109.95 | 2019-2022 | |
| Amgen INC. | $75.20 | 2020-2022 | |
| Novo Nordisk INC | $33.54 | 2020 | |
| Boston Scientific Corporation | $30.26 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $26.82 | 2021-2022 | |
| Recordati_rare_diseases_inc. | $20.92 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $16.06 | 2020 | |
| Abbott Laboratories | $14.99 | 2019 | |
| Bard Peripheral Vascular, INC. | $13.71 | 2021 | |
| Merck Sharp & Dohme LLC | $11.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunita Ravikumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.